2,088
Trials as lead sponsor
Most active programmes
The drugs appearing most often across AbbVie's recently active trials. Comparator arms are excluded.
- Carboplatin9 trials
- Telisotuzumab Adizutecan6 trials
- Venetoclax6 trials
- Risankizumab6 trials
- Bevacizumab5 trials
- Upadacitinib5 trials
Upcoming readouts
Next primary completion dates among AbbVie's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Oct 2026A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate…Phase 2
- May 2027Ubro Peds: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Tre…Phase 3
- Nov 2027A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Par…Phase 2
- Feb 2028A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Thr…Phase 2
- Feb 2028A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-…Phase 2
- Mar 2028A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in…Phase 3
Top therapeutic areas
Conditions studied most often across AbbVie's recently active trials.
- Non-Small Cell Lung Cancer5 trials
- Acute Myeloid Leukemia4 trials
- Ulcerative Colitis4 trials
- Atopic Dermatitis4 trials
- Crohn's Disease3 trials
- Ovarian Cancer3 trials
AbbVie pipeline by phase
The main study drugs across 211 active trials AbbVie leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 328 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Upadacitinib | 16 | 5 | Jan 2027 est. | NCT07772492 · NCT07023302 · NCT06701331 |
| Telisotuzumab AdizutecanABBV-400 | 15 | 8 | Dec 2026 est. | NCT07525206 · NCT06614192 · NCT07769502 |
| Risankizumab | 11 | 6 | Jan 2027 est. | NCT07071519 · NCT06880744 · NCT05995353 |
| EtentamigTNB-383B | 10 | 4 | Dec 2027 est. | NCT07793422 · NCT07728188 · NCT06158841 |
| Lutikizumab | 7 | 3 | Dec 2026 est. | NCT06468228 · NCT06972446 · NCT06865105 |
| Atogepant | 5 | 3 | Mar 2028 est. | NCT06810505 · NCT06806293 · NCT05711394 |
| Surabgene LomparvovecRGX-314 | 5 | 2 | Oct 2026 est. | NCT07007065 · NCT05407636 · NCT07592273 |
| Ubrogepant | 4 | 2 | Oct 2026 est. | NCT06417775 · NCT05127954 · NCT05125302 |
| ABBV-706 | 3 | 2 | Nov 2027 est. | NCT07365241 · NCT07155174 · NCT05599984 |
| Telisotuzumab vedotin | 3 | 2 | Feb 2028 est. | NCT04928846 · NCT06568939 · NCT03539536 |
| Adalimumab | 2 | 1 | — | NCT06100744 · NCT02629159 |
| Navitoclax | 2 | — | Dec 2026 est. | NCT04468984 · NCT04041050 |
| 25mg Eluxadoline | 1 | — | Dec 2032 est. | NCT04880876 |
| ABBV-1480 | 1 | — | Dec 2029 est. | NCT07756645 |
| ABBV-444 | 1 | — | — | NCT07284381 |
| ARTIA Reconstructive Tissue Matrix | 1 | 1 | Feb 2031 est. | NCT06575192 |
| Cariprazine | 1 | 1 | Mar 2027 est. | NCT04777357 |
| Elagolix | 1 | — | Jul 2027 est. | NCT04333576 |
| ELAPR002f Injectable Gel | 1 | 1 | Nov 2029 est. | NCT07207369 |
| HArmonyCa Lidocaine Injectable Gel | 1 | — | — | NCT07032597 |
| Mirvetuximab soravtansine plus Bevacizumab | 1 | — | Apr 2027 est. | NCT05445778 |
| NOA LIFT | 1 | 1 | Aug 2028 est. | NCT07794878 |
| NOA VOLUME | 1 | 1 | Jul 2029 est. | NCT06734351 |
| Risankizumab IV | 1 | — | Feb 2029 est. | NCT03105102 |
| Risankizumab SC | 1 | — | Mar 2027 est. | NCT06063967 |
| Upadacitinib (ABT-494) | 1 | — | Jul 2027 est. | NCT03006068 |
| Upadacitinib 15mg Dose | 1 | 1 | — | NCT06389136 |
| XEN63 Glaucoma Treatment System | 1 | 1 | Nov 2028 est. | NCT06822738 |
Phase 219 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Livmoniplimab | 5 | 2 | Feb 2027 est. | NCT06632951 · NCT06236438 · NCT06109272 |
| ABBV-932 | 4 | 3 | Nov 2026 est. | NCT07220460 · NCT06846320 · NCT07071532 |
| Mirvetuximab soravtansine | 4 | 2 | Nov 2026 est. | NCT07059845 · NCT06682988 · NCT06365853 |
| ABBV-295 | 3 | 2 | Jan 2027 est. | NCT07752979 · NCT07514260 · NCT07291232 |
| AGN-151586 | 2 | 2 | Oct 2026 est. | NCT07730554 · NCT07756580 |
| AGN-151607-DP | 2 | 2 | Sept 2028 est. | NCT07673107 · NCT07226791 |
| Emraclidine | 2 | 2 | Dec 2026 est. | NCT07145918 · NCT07219030 |
| Icalcaprant | 2 | 2 | Sept 2027 est. | NCT07276997 · NCT06696755 |
| IMGN151 | 2 | 1 | Feb 2027 est. | NCT07024784 · NCT05527184 |
| Pivekimab Sunirine | 2 | 2 | Apr 2028 est. | NCT07581002 · NCT07306832 |
| ABBV-142 | 1 | 1 | Sept 2029 est. | NCT07230288 |
| Armour Thyroid | 1 | 1 | Sept 2027 est. | NCT06345339 |
| Budigalimab | 1 | — | Nov 2026 est. | NCT05822752 |
| Carfilzomib | 1 | — | Jun 2027 est. | NCT02899052 |
| Eluxadoline | 1 | 1 | Dec 2026 est. | NCT03339128 |
| Local Steroid | 1 | — | — | NCT04514653 |
| MEDI0618 | 1 | 1 | Dec 2026 est. | NCT06602479 |
| Standard of Care | 1 | 1 | Dec 2031 est. | NCT07005102 |
| Topical Steroid | 1 | — | — | NCT04567550 |
Phase 135 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| ABBV-319 | 2 | 1 | Feb 2027 est. | NCT06977724 · NCT05512390 |
| ABBV-927 | 2 | — | Mar 2027 est. | NCT03893955 · NCT02988960 |
| ABBV-101 | 1 | — | Mar 2031 est. | NCT05753501 |
| ABBV-1042 | 1 | 1 | — | NCT07222709 |
| ABBV-1451 | 1 | 1 | Apr 2027 est. | NCT07570147 |
| ABBV-1758 | 1 | 1 | Oct 2030 est. | NCT07599670 |
| ABBV-243 | 1 | 1 | May 2027 est. | NCT07306754 |
| ABBV-253 | 1 | — | Dec 2029 est. | NCT07807956 |
| ABBV-291 | 1 | — | Apr 2027 est. | NCT06667687 |
| ABBV-313 | 1 | 1 | Feb 2028 est. | NCT07673120 |
| ABBV-324 | 1 | 1 | Sept 2030 est. | NCT06858813 |
| ABBV-438 | 1 | 1 | Nov 2031 est. | NCT07409246 |
| ABBV-453 | 1 | — | — | NCT05308654 |
| ABBV-519 | 1 | 1 | Jan 2029 est. | NCT07607964 |
| ABBV-525 | 1 | — | Jul 2029 est. | NCT05618028 |
| ABBV-547 | 1 | — | Aug 2027 est. | NCT07232004 |
| ABBV-637 | 1 | — | — | NCT04721015 |
| ABBV-6628 | 1 | 1 | Oct 2029 est. | NCT07160179 |
| ABBV-701 | 1 | — | Nov 2026 est. | NCT06895343 |
| ABBV-711 | 1 | 1 | Apr 2029 est. | NCT07241039 |
| ABBV-722 | 1 | — | — | NCT07599761 |
| ABBV-744 | 1 | — | Jan 2027 est. | NCT04454658 |
| ABBV-859 | 1 | 1 | Feb 2027 est. | NCT07736638 |
| ABBV-901 | 1 | 1 | Jan 2029 est. | NCT07278336 |
| ABBV-969 | 1 | — | May 2027 est. | NCT06318273 |
| AGN-193408 SR | 1 | — | Apr 2029 est. | NCT04499248 |
| Azirkitug | 1 | 1 | Jul 2027 est. | NCT05005403 |
| Bretisilocin | 1 | — | — | NCT07604558 |
| Etentamig (ABBV-383) | 1 | 1 | Aug 2029 est. | NCT05650632 |
| IMGN632 | 1 | — | — | NCT03386513 |
| Nacresertib | 1 | 1 | — | NCT07649954 |
| Obinutuzumab | 1 | — | Jul 2027 est. | NCT06291220 |
| Osimertinib | 1 | — | — | NCT02099058 |
| Subcutaneous (SC) Etentamig | 1 | — | Feb 2027 est. | NCT06223516 |
| Surzetoclax | 1 | 1 | Dec 2030 est. | NCT06953960 |
Phase 43 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Venetoclax | 8 | 3 | Nov 2026 est. | NCT07044687 · NCT05144243 · NCT06428019 |
| OnabotulinumtoxinA | 1 | — | Jun 2027 est. | NCT07794891 |
| XEN45 Glaucoma Treatment System | 1 | — | Jul 2030 est. | NCT05821855 |
Combination backbones Azacitidine (2 trials), Dexamethasone (2 trials), Carboplatin (1 trial). Established agents these trials combine with, listed separately from the drugs under study.
Derived from 211 active trials AbbVie leads; 188 name an intervention, folding into 85 phased drugs. This is ComplyRx's reading of the registry, not AbbVie's own pipeline disclosure.
AbbVie trials
The 50 most significant of AbbVie's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult ParticipantsNCT07730554AGN-151586 | Phase 2 | Not yet scored | OngoingRecruiting | 80 est. | Oct 2026 |
| Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult ParticipantsNCT07680686Ubrogepant | Phase 1 | Not yet scored | OngoingRecruiting | 52 est. | Oct 2026 |
| ESVECOA Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaNCT05587049 | — | Not yet scored | OngoingRecruiting | 70 est. | Nov 2026 |
| A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult ParticipantsNCT07219030Emraclidine | Phase 1 | Locked · track to reveal | OngoingRecruiting | 52 est. | Dec 2026 |
| IntrepidA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT06468228Lutikizumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,400 est. | Dec 2026 |
| ONIROSA Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/FoscarbidopaNCT07284342 | — | Not yet scored | OngoingRecruiting | 103 est. | Jan 2027 |
| A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.NCT07514260ABBV-295 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 24 est. | Jan 2027 |
| A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar DisorderNCT07071532ABBV-932 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 20 est. | Feb 2027 |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionNCT06365853Mirvetuximab Soravtansine | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 108 est. | Feb 2027 |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)NCT05512390ABBV-319 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 39 est. | Feb 2027 |
| A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)NCT06487559Livmoniplimab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 3 est. | Feb 2027 |
| A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesNCT07756580AGN-151586 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 120 est. | Mar 2027 |
| ConFeRStudy to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) CountriesNCT07539844 | — | Not yet scored | OngoingRecruiting | 1,000 est. | Mar 2027 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsNCT03893955ABBV-927 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 150 est. | Mar 2027 |
| OPTIMAL-3A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular EdemaNCT07604545 | — | Not yet scored | StoppedWithdrawn | 0 est. | Mar 2027 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaNCT06667687ABBV-291 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 21 est. | Apr 2027 |
| Ubro PedsStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)NCT05125302Ubrogepant | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,059 est. | May 2027 |
| EMBARKA Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisNCT06718101Lutikizumab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 83 est. | May 2027 |
| Study to Assess Participant Satisfaction After Jawline and Neck TreatmentNCT07794891OnabotulinumtoxinA | Phase 4 | Not yet scored | OngoingNot yet recruiting | 100 est. | Jun 2027 |
| 453 Ph1 CLLA Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT06291220Obinutuzumab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 4 est. | Jul 2027 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481ABBV-400 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 325 est. | Sept 2027 |
| Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)NCT06916507 | — | Not yet scored | OngoingRecruiting | 125 est. | Sept 2027 |
| UP-TAINEDA Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World SettingNCT05139836 | — | Locked · track to reveal | OngoingActive, not recruiting | 634 est. | Sept 2027 |
| P25-758 PUCCINReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson DiseaseNCT07227896 | — | Not yet scored | OngoingRecruiting | 100 est. | Oct 2027 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in IndiaNCT07044687Venetoclax | Phase 4 | Locked · track to reveal | OngoingRecruiting | 100 est. | Nov 2027 |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II DisorderNCT06696755Icalcaprant | Phase 2 | Locked · track to reveal | OngoingRecruiting | 195 est. | Nov 2027 |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623Telisotuzumab Adizutecan | Phase 1 | Locked · track to reveal | OngoingRecruiting | 252 est. | Nov 2027 |
| UBRO MMStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06417775Ubrogepant | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 496 est. | Nov 2027 |
| CERVINOStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06158841Etentamig | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 421 est. | Dec 2027 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With SchizophreniaNCT07145918Emraclidine | Phase 2 | Locked · track to reveal | OngoingRecruiting | 268 est. | Feb 2028 |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06568939Telisotuzumab Vedotin | Phase 2 | Locked · track to reveal | OngoingRecruiting | 150 est. | Feb 2028 |
| A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineNCT05711394Atogepant | Phase 3 | Locked · track to reveal | OngoingRecruiting | 450 est. | Mar 2028 |
| Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979ABBV-295 | Phase 2 | Not yet scored | OngoingRecruiting | 360 est. | Mar 2028 |
| AndroMETa-CRCA Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerNCT06820463Telisotuzumab Adizutecan | Phase 2 | Locked · track to reveal | OngoingRecruiting | 390 est. | Mar 2028 |
| DREAMStudy to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque PsoriasisNCT07039110 | — | Locked · track to reveal | OngoingRecruiting | 700 est. | Mar 2028 |
| Step-Up HSA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyNCT05889182Upadacitinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,328 est. | Mar 2028 |
| A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)NCT07306832Pivekimab Sunirine | Phase 1 | Locked · track to reveal | OngoingRecruiting | 18 est. | Apr 2028 |
| NAAVIGATESurabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaNCT07592273Surabgene Lomparvovec | Phase 2 | Locked · track to reveal | OngoingRecruiting | 576 est. | Jun 2028 |
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)NCT07387471Venetoclax | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 14 est. | Jul 2028 |
| Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in AdultsNCT07794878NOA LIFT | Phase 3 | Not yet scored | OngoingRecruiting | 288 est. | Aug 2028 |
| Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia RepairNCT07226791AGN-151607-DP | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | Sept 2028 |
| A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With GlaucomaNCT06822738XEN63 Glaucoma Treatment System | Phase 3 | Locked · track to reveal | OngoingRecruiting | 130 est. | Nov 2028 |
| A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersNCT07769502Telisotuzumab Adizutecan | Phase 2 | Not yet scored | OngoingNot yet recruiting | 168 est. | Nov 2028 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846Telisotuzumab Vedotin | Phase 3 | Locked · track to reveal | OngoingRecruiting | 768 est. | Dec 2028 |
| FLORENZAA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerNCT07059845Mirvetuximab Soravtansine | Phase 2 | Locked · track to reveal | OngoingRecruiting | 400 est. | Jan 2029 |
| A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07607964ABBV-519 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | Jan 2029 |
| FORTIFYA Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's DiseaseNCT03105102Risankizumab IV | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,336 est. | Feb 2029 |
| RISEA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseNCT05995353Risankizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 110 est. | Apr 2029 |
| SEZanneA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174ABBV-706 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 180 est. | Apr 2029 |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsNCT07241039ABBV-711 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 220 est. | Apr 2029 |